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T
he RNA interference (RNAi) technique
based on small interfering RNA (siRNA)
ormicroRNA (miRNA) has shown great
potential for cancer therapy given its unique
sequence-speciﬁc gene silencing eﬀect.13
However, clinical translation of RNAi has
stalled over a decade due to the diﬃculties
in deliveringRNAs into the tumor tissues and,
more importantly, into the tumor cells in vivo.
The key to overcoming this challenge is
to deliver RNAs eﬀectively into host cells. A
number of RNA delivery systems based on
cationic polymers, lipids, or amino acids have
been developed for in vitro applications,46
topical delivery in vivo,7,8 or a limited number
of systemic delivery systems in vivo that are
mainly conﬁned to liver or lung targeted
applications.9,10 The development of simple,
safe, and versatile platforms for systemic
delivery of RNAis to tumor cells remains
a grand challenge.1113 To overcome these
limitations, herein, we report a versatile RNAi
nanoplatform based on tumor-targeted and
pH-responsive RNA nanoformulas (NFs) that
can deliver a wide range of RNAi agents into
tumor cells in vivo by systemic administra-
tion. We substantiated the versatility of this
RNAi delivery system by demonstrating its
eﬀective delivery of both siRNA and miRNA
into three diﬀerent human cancer cell lines
(144B, DU145, and HCT116) and into HCT116
tumor-bearing mice by intravenous injec-
tion. Systemic administration of this nano-
carrier system demonstrates its ability to
overcome obstaclesmet under physiological
conditions.
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ABSTRACT Development of nontoxic, tumor-targetable, and
potent in vivo RNA delivery systems remains an arduous challenge
for clinical application of RNAi therapeutics. Herein, we report
a versatile RNAi nanoplatform based on tumor-targeted and
pH-responsive nanoformulas (NFs). The NF was engineered by
combination of an artiﬁcial RNA receptor, Zn(II)-DPA, with a
tumor-targetable and drug-loadable hyaluronic acid nanoparticle,
which was further modiﬁed with a calcium phosphate (CaP) coating
by in situ mineralization. The NF can encapsulate small-molecule drugs within its hydrophobic inner core and strongly secure various RNA molecules
(siRNAs, miRNAs, and oligonucleotides) by utilizing Zn(II)-DPA and a robust CaP coating. We substantiated the versatility of the RNAi nanoplatform by
demonstrating eﬀective delivery of siRNA and miRNA for gene silencing or miRNA replacement into diﬀerent human types of cancer cells in vitro and into
tumor-bearing mice in vivo by intravenous administration. The therapeutic potential of NFs coloaded with an anticancer drug doxorubicin (Dox) and
multidrug resistance 1 gene target siRNA (siMDR) was also demonstrated in this study. NFs loaded with Dox and siMDR could successfully sensitize drug-
resistant OVCAR8/ADR cells to Dox and suppress OVCAR8/ADR tumor cell proliferation in vitro and tumor growth in vivo. This gene/drug delivery system
appears to be a highly eﬀective nonviral method to deliver chemo- and RNAi therapeutics into host cells.
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A
RTIC
LE
CHOI ET AL. VOL. 8 ’ NO. 5 ’ 4559–4570 ’ 2014
www.acsnano.org
4560
Several critical factors should be considered when
designing potent in vivo RNA delivery systems: (i)
securing of RNAs to delivery carriers; (ii) in vivo tumor
targeting and cell permeation; (iii) RNA release from
delivery carriers; (iv) homogeneous distribution of
RNAs in the cytosol after endosomal escape.3,12,13
To meet these requirements, we engineered a nano-
carrier (NC) that can strongly secure RNA molecules
using artiﬁcial RNA receptors, deliver RNAs into the
tumor cells via receptor-mediated endocytosis,
and release RNAs into the cytosol of cancer cells
(Figure 1).
The NC system is mainly based on tumor-cell-
speciﬁc and drug-loadable HA-based nanoparticles
(HA-NPs) that we recently developed.14,15 The HA-
NPs are formed by self-assembly of engineered
hyaluronan-5β-cholanic acid (HA-CA) conjugates, as a
NC platform for hydrophobic, small-molecule anti-
cancer drugs.16,17 The main components are made of
naturally occurring glycosaminoglycan HA conjugated
with a bile acid analogue, CA (Supporting Information
Figure S1c). The use of naturally occurring biomole-
cules decreases the likelihood of safety concerns that
are associated with synthetic materials. These are ideal
NCs for cytotoxic/anticancer drugs because HA-NPs
can selectively target tumors not only by passive
accumulation in the leaky vasculature of tumor tissues
but also by active binding onto and penetration into
cancer cells via receptor-mediated endocytosis after
binding to HA receptor, CD44, which is overexpressed
on various tumors.1820
Although the HA-NP serves as an ideal nanocarrier
platform for delivery of small-molecule anticancer
drugs, it is, however, not by itself capable of RNA
delivery. The HA-NP is composed of a highly anionic
polymer that cannot form polyelectrolyte complexes
with anionic RNA for facile cellular delivery. In this
study, therefore, an artiﬁcial RNA receptor, Zn(II)-
dipicolylamine (DPA/Zn) which has a high aﬃnity for
RNAs via speciﬁc interactions between coordinated zinc
ions of DPA and anionic phosphates of the RNA,2123
was utilized to functionalize the HA-NP system
(Supporting Information Figure S1d). Unlike most re-
ported gene delivery systems that are based on cationic
derivatives or chemically modiﬁed RNAs, this nanofor-
mula exploits an engineered RNA receptor, DPA/Zn. This
DPA/Zn-labeled HA-NP (HDz) NC system takes advan-
tage of the phosphate binding properties of DPA/Zn to
bind RNAs and tumor cell targetability of HA-NP. More-
over, since RNA agents and hydrophobic anticancer
drugs can be simultaneously loaded onto the surface
and inner cores of this HDz nanocarrier, respectively, in
a facile manner, this nanocarrier can exert synergistic
eﬀects associated with codelivery of these two diﬀerent
therapeutic avenues. This combination enables intracel-
lular delivery of RNAs and/or chemotherapeutics in vivo
with enhanced cell permeability, tumor targetability,
and low toxicity.
Figure 1. Schematic illustration of hypothetical tumor-targeting, cellular uptake, RNA release, and degradation pathway of
CaP-HDz/RNA-NF. (1,2) The nanoformula (NF) can deliver both RNAs and lipophilic drug molecules into the tumor cells via
systemic accumulation as well as CD44-mediated endocytosis. (3) NF releases RNAs in late endosomes or early lysosomes
(pH∼4.55.5) with the CaP layer dissolved in the acidic environment, releasing calcium and phosphate ions. (4) NFs and RNA
molecules can escape from endosomes likely due to the increased osmotic pressure in endosomes, which can cause
endosomal swelling and consequent endosomal escape of RNAs. After the endosomal escape, RNAs can be distributed evenly
into the cytosol of cancer cells, which results in selective suppression of target genes. (5) NFs can be further degraded by HA
enzyme, hyaluronidases (Hyals), resulting in collapse of nanostructure and release of all the payloads (e.g., lipophilic small-
molecule drugs).
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Despite the strong complexation of RNAs with HDz-
NCs, HDz/RNA-NFs still face diﬃculties in practical use
because the phosphate-speciﬁc binding between
RNAs and DPA/Zn can be perturbed by endogenous
phosphate anions in the physiological environment.24
Given considerably high phosphate concentration
in the cell culture medium or the bloodstream, the
NFs necessitate further protection from phosphate
molecules in vitro and in vivo. Therefore, we added
complementary calcium phosphate (CaP) layers onto
the HDz/RNA-NFs by in situ mineralization of sequen-
tially added calcium and phosphate ions. The robust
CaP precipitate coating signiﬁcantly increases the NFs'
ability to secure RNAs under phosphate-rich physio-
logical conditions.
Moreover, the CaP coating facilitates pH-dependent
RNA release and endosomal escape. The CaP precipi-
tate rapidly dissolves at acidic pH (pH <6), releasing
nontoxic calcium and phosphate ions.25 After CD44-
mediated endocytosis, the CaP layer can be dissolved
in late endosomes or early lysosomes (pH 4.55.5),
releasing calcium and phosphate ions. As the CaP layer
is removed, RNAs incorporated onto the HDz-NCs can
be uncovered. The phosphate ions released from the
nanoformulas competitively bind with DPA/Zn recep-
tors and, consequently, can trigger RNA release from
the HDz/RNA-NFs. The HA-based backbone can be
degraded by HA enzymes, hyaluronidases (Hyals), in-
side the tumor cells,28,29 which result in NP collapse
and subsequent release of small-molecule chemother-
apeutics or other payloads from the NFs. Furthermore,
like polymers with low pKa amine groups, the ionic
components released from CaP-HDz/RNA-NFs can
deplete protons in an acidic environment, and they
are capable of buﬀering the endosomes, increasing
osmotic pressure of endosomes, leading to endosomal
swelling and lysis, which subsequently results in re-
lease of nucleic acids into the cytoplasm as previously
reported.26,27
RESULTS AND DISCUSSION
The engineered nanocarrier for RNA delivery is
composed of four major components (Figure 2a): (i) a
hydrophilic hyaluronan (HA) shell as CD44-targeting
ligand; (ii) hydrophobic 5β-cholanic acid (CA) inner
core as a drug reservoir; (iii) a phosphate receptor
Zn(II)-dipicolylamine (DPA/Zn), as a RNA binding site;
(iv) a calcium phosphate layer. To prepare the NC, we
functionalized the HA-NPs with phosphate receptor,
DPA/Zn, to serve as a RNA binding site (Supporting
Information Figure S1d). First, hydrophilic HA and
hydrophobic CA molecules were conjugated as pre-
viously reported;14,15 the amphiphilic conjugate can
form self-assembled nanoparticles (HA-NPs) that deli-
ver hydrophobic, small-molecule anticancer drugs.16,17
Second, to prepare the HDz nanocarrier, amine-
functionalized bis(DPA) molecules were covalently
conjugated with the carboxylic groups on the HA
backbone of HA-NPs.24 The 1H NMR analysis indicated
that 15.5 ( 3.4 molecules of CA and 28.5 ( 4.2
molecules of bis(DPA) were bound onto the HA back-
bone of HDz conjugate (Supporting Information
Figure S2). The HDz conjugates were self-assembled
in aqueous solution, forming nanosized particles with
an average hydrodynamic diameter of 94.3 ( 3.5 nm
(Figure 2b).
The HDz-NCs were readily complexed with a variety
of RNAi agents (siRNA, miRNA, or oligonucleotide) by
mixing RNAs with NCs. The gel electrophoresis images
showed signiﬁcant retardation of RNAmolecules (1 μL,
266 ng, 20 pmol) formulated with HDz-NCs (2 μL, 2 μg,
7.3 pmol), indicating successful incorporation of RNAs
onto the HDz-NCs (Figure 2c,e,f). After HDz-NCs were
formulated with RNAmolecules, the mean diameter of
HDz/RNA-NFs increased by approximately 15 nm (from
94.3 ( 3.5 to 108.8 ( 1.8 nm), and the surface charge
decreased from 25.1 ( 0.9 to 30.9 ( 2.0 mV due
to the incorporation of negatively charged RNA mol-
ecules onto the HDz-NC (Figure 2b). The incorporation
of RNAs onto HDz-NCs is based on the strong, selective
binding of DPA/Zn toward diphosphate groups of the
RNA backbone. The binding of RNAs with DPA/Zn
ligands was disrupted by the addition of excess phos-
phate ions (Na3PO4, 1.2 μmol) (Figure 2d) but was not
aﬀected by other molecules (i.e., NaCl, MgCl2).
24
In an eﬀort to better secure RNAs as well as to
facilitate pH-dependent RNA release, we modiﬁed
the HDz/RNA-NCs with a calcium phosphate layer by
in situmineralization onto the NFs. RNAs incorporated
onto the NFs are stable even after incubation with an
excess amount of phosphate ions (Na3PO4, 1.2 μmol),
indicating that the CaP layer can help protect RNAs
under physiological conditions (pH ∼7.4) (Figure 2d).
The CaP-HDz/RNA-NFs exhibited slightly negative sur-
face charge (5 ( 1.1 mV) and 196 ( 35.6 nm hydro-
dynamic size (Figure 2b). AFM analyses demonstrated
that over 95% of the CaP-HDz/RNA-NFs were uniformly
dispersed as single, spherical particles (124.2 (
47.8 nm). Clusters with relatively large particle sizes
(310.0 ( 31.3 nm) were found in less than 5% of
the whole population in AFM images (Figure 2e,f).
The cluster formation was not detected in the DLS
measurement. The smaller size distribution of NFs and
the cluster formation found in the AFM analyses may
be attributed to the drying process of the AFM sample
preparation.
With phosphate ions released from the NFs in acidic
environment, RNA release can be triggered by com-
petitive binding between the CaP layer released
phosphate anions and RNA complexes for DPA/Zn
receptors. In this study, the pH-dependent RNA release
proﬁles of CaP-HDz/RNA-NFs were studied using
gel electrophoresis. At neutral pH (pH 7.4), RNAs
were ﬁrmly incorporated with CaP-HDz-NCs, showing
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substantial retardation of RNA release; however, sig-
niﬁcant RNA release (52.8 ( 1.3%) was observed at
slightly acidic pH (5.0 or 6.0 pH), implying that the NFs
can release RNAs in acidic intracellular compartments
such as endosomes (pH∼5.0) and lysosomes (pH∼4.5)
(Figure 3b,c). Meanwhile, the NP degradation and drug
release behavior of NFs were monitored using ﬂuores-
cence microscopy. As a ﬂuorescent model drug,
Oregon green labeled paclitaxel (PTX-OG) was loaded
into the CaP-HDz/siRNA-NFs. After loading, the ﬂuo-
rescence of PTX-OG was highly quenched, indicating
compact encapsulation of PTX-OG molecules in the
hydrophobic cores of NFs. However, when the NFs
were exposed to Hyal, ﬂuorescence intensities were
signiﬁcantly recovered due to the release of PTX-OG
from the NFs. With the increase of Hyal concentration,
the NF backbone was further degraded and additional
PTX-OG molecules were released, thus increasing the
ﬂuorescence intensity (Figure 3d,e).
In addition, we tested the stability of siRNA com-
plexed with CaP-HDz-NCs in the physiological condi-
tion (Supporting Information Figure S4). siRNA
formulatedwith CaP-HDz-NCs and free siRNA (15 pmol)
were incubated in themouse serum for 1, 6, and 24 h at
37 C. Sequentially, the samples were incubated at pH 5
for 20 min to emulate the endosome/lysosome acidic
environment. After the incubation, intact RNA amount
in the samples was evaluated by gel electrophoresis
Figure 2. Preparation of CaP-HDz/RNA-NF. (a) NFs can strongly secure RNA molecules (and small-molecule lipophilic drugs
if needed) using artiﬁcial RNA receptors (Zn/DPA) as well as a CaP-layer. (b) Zeta-potential results of HDz-NP, HDz/siRNA-NF,
Ca-HDz/siRNA-NF, and CaP-HDz/siRNA NF. Electrophoretic retardation analysis of siRNA (c,d), miRNA (e), and oligonucleotide
(f) (all at 10 pmol) binding with HDz and CaP-HDz-NP (all at 2 μg of HDz-NP). The siRNA, miRNA, and oligonucleotide are
securely complexed with HDz and CaP-HDz at neutral pH (pH 7.4). Release of siRNA from HDz/siRNA was observed after
addition of phosphate ions. However, siRNA molecules were secured on CaP-HDz/siRNA-NFs with phosphate ions added.
AFM image of representative CaP-HDz/siRNA-NFs (g) and histogram of the diameter (h). Scale bar, 500 nm.
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analyses. The CaP-HDz/siRNA samples contained
higher amount of siRNA compared with the free siRNA
samples. After the serum incubation for 24 h, over 70%
of siRNA loaded in the NFs were found to be intact,
whereas free siRNA sampleswere completely degraded
after 24 h incubation with serum. This indicates that
CaP-HDz/siRNA-NFs can bemaintained relatively stable
in physiological serum conditions, protecting siRNAs
from enzymatic degradation.
Prior to functional, biological studies, we examined
the cellular uptake of HA/DPA-Zn-NP/siRNA in cancer
cells (DU145 and 143B). To demonstrate cell permea-
tion attributes of the NFs, we treated CD44-positive
DU145 cancer cells with CaP-HDz/Cy3-RNA-NFs,
Lipo2K/Cy3-RNA, or LipoMax/Cy3-RNA and monitored
intracellular ﬂuorescence signals using confocal ﬂuo-
rescence microscopy. We also conﬁrmed the cellular
uptake eﬃciency of CaP-HDz/Cy3-RNA in CD44-
positive DU145 cancer cells. The transfection eﬃciency
of Cy3-RNA was quantitatively evaluated using ﬂow
cytometry. Overall, the NFs readily penetrated into
andwere evenly distributed in cells 1 h after treatment.
Strong ﬂuorescence signals were detected in cells
incubated with CaP-HDz/Cy3-RNA-NFs, whereas lower
ﬂuorescence signals were observed from cancer cells
treated with Lipo2K/Cy3-RNA or LipoMax/Cy3-RNA.
Mean ﬂuorescence intensity of CaP-HDz/Cy3-RNA-NF
group was 3.2- to 3.8-fold higher than that of Lipo2K/
Cy3-RNA or LipoMax/Cy3-RNA group in both cell lines
(Supporting Information Figure S5ac).
To better understand if the HA receptor CD44
mediates endocytosis of the NFs, we performed com-
petitive binding studies. CD44 receptors on 143B cells
were ﬁrst blocked with excess amount of free HAmole-
cules, and then the cells were treated with Cy5.5-
labeled CaP-HDz-NC complexed with Cy3-labeled RNA.
After 1 h incubation, intracellular ﬂuorescence signals
were evaluated. The ﬂuorescence intensities from both
Figure 3. (a) RNA release and degradationmechanism of CaP-HDz/siRNA-NF. With the CaP layer dissolved in late endosomes
or early lysosomes (pH 4.55.5), the NFs can free RNA molecules. Phosphate ions released from the NFs competitively bind
with DPA/Zn receptors and, consequently, can trigger RNA release from the HDz/RNA-NFs. Furthermore, the HA-based
backbone can be degraded by Hyals in the tumor cells, which can result in NF collapse and release of drug payloads from
the NFs. (b,c) siRNA complexed with CaP-HDz-NFs can be ﬁrmly secured at neutral pH (pH 7.4) but are readily released from
CaP-HDz-NP in endosomal/lysosomal pH conditions (pH 6 and 5). (d,e) Monitoring of enzyme-triggered NF degradation and
drug release from NFs incorporated with both lipophilic drug, paclitaxel (PTX), and siRNA. To visualize NF degradation and
drug release proﬁle, the HDz-NPs were labled with Cy5.5 (HDz-Cy5.5), and PTX was labeled with Oregon green (PTX-OG).
Fluorescent images of CaP-HDz-Cy5.5/PTX-OG/siRNA-NFs were collected after incubation with diﬀerent concentrations
(0, 2.5, 25, 250 units/mL) of Hyal in acetate buﬀer (pH = 4.3, 37 C) for 1 h. When PTX-OG was compactly encapsulated in the
NFs, the ﬂuorescence of PTX-OG was highly quenched. However, after the NFs were incubated with Hyal, ﬂuorescence
intensities signiﬁcantly increased, indicating NF degradation and consequent bursting release of PTX-OG from NFs.
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Cy5.5-NCs and Cy3-RNAs considerably decreased com-
pared to those from NF-treated HCT116 cells without
CD44 blocking (Supporting Information Figure S5d).
These results demonstrated that the strong interaction
between the CD44 and HA shell of HDz-NCs plays a
pivotal role in cell permeation, although the surface
of the NFs is partially covered with a CaP layer. This
shows that CaP-HDz/RNA-NFs can bind onto and
permeate into cancer cells primarily via CD44-mediated
endocytosis.
Furthermore, we studied endosomal escape traits of
CaP-HDz/RNA-NFs. We labeled endosomes with endo-
some staining agent (LysoTracker Blue DND-22,
Invitrogen) after 6 h incubation of cancer cells with
CaP-HDz/Cy3-RNAs. RNAs and endosomes were then
imaged using confocal ﬂuorescence microscopy. After
6 h incubation, siRNAs were separated from NCs and
endosomes. RNAs were evenly distributed in the cyto-
plasm, indicating that RNAs were successfully disso-
ciated from NCs, escaped from the endosome, and
distributed into the cytoplasm (Supporting Informa-
tion Figure S6). The results may be due to the pH-
dependent calciumandphosphate ion release in acidic
pH environments of intracellular compartments like
endosomes, which increases intraendosomal osmotic
pressure and induces membrane disruption of endo-
somes and then escape of RNAs from endosomes.26,27
After intracellular traﬃcking of the NFs, we investi-
gated RNAi-based gene silencing utility using CaP-
HDz/RNAs-NFs. Since the aim of this research is
to develop a versatile nanoplatform for in vivo RNA
delivery, we prepared three types of NFs containing
three diﬀerent model RNAs: ﬁreﬂy luciferase (fLuc)
gene-targeting siRNA (siLuc); green ﬂuorescence pro-
tein (GFP) gene-targeting siRNA (siGFP); or microRNA-
34a (miR34a). To evaluate the RNAi activity of the NFs
in vitro and in vivo, we established three cancer cell
lines that stably express fLuc, GFP, or miR34a reporter
gene vector: 143B-fLuc, DU145-GFP, or HCT116-
miR34a. The RNAi eﬀect can thus be assessed by
optical-imaging-based facile, quantitative evalua-
tion methods. The ability of CaP-HDz-NCs to deliver
aforementioned RNAs into the cancer cells was quan-
titatively evaluated by measuring expression levels
of fLuc, GFP, or miR34a in 143B-fLuc, DU145-GFP, or
HCT116-miR34a treated with CaP-HDz/siLuc, CaP-HDz/
siGFP, or CaP-HDz/miR34a NFs, respectively. The cells
treated with corresponding free RNAs or RNAs with
Lipo2K or LipoMax were tested as negative or positive
control groups. Free siLuc did not show any distinct
fLuc gene suppression eﬀect since cells do not readily
take up large, negatively charged molecules. Negative
control siRNA (siNC) formulated with NCs (CaP-HDz/
siNC-NFs) or Lipo2K (Lipo2K/siNC) also did not display
gene silencing eﬀect. When formulated with CaP-HDz,
only 71.2( 16.7 fmol of siLuc was needed to suppress
the fLuc gene expression level by 50%. After the cells
were treated with 5 pmol of siLuc incorporated with
NFs, the fLuc gene expression level was dropped by
92.7 ( 2.5%. However, when siLuc is complexed with
Lipo2K, almost 30 times higher dose of siLuc (1.9 (
2.0 pmol) was needed to get 50% fLuc gene suppres-
sion (Figure 4a,b and Supporting Information Figure
S7a,b).
The excellent gene silencing eﬀect of CaP-HDz/
siRNA-NFs was conﬁrmed with a diﬀerent siRNA
(siGFP) in aDU145-GFPcancer cell line. Asdemonstrated
with siLuc, treatment of free siGFP, CaP-HDz/siNC-NF, or
Lipo2K/siNC did not achieve any gene knockdown in
DU145-GFP cells (Figure 4f and Supporting Information
Figure S7d,e). On the other hand, CaP-HDz/siGFP-NFs
did suppress GFP gene expression by 50% at a siGFP
dose of 60.7 ( 12.7 fmol after incubation with DU145-
GFP cells for 24 h. Furthermore, at a siGFP dose of
0.3 pmol, the NFs reached 91.8 ( 0.5% gene silencing.
A 17-fold higher dose of siGFP (5 pmol) complexed
with Lipo2K only attained 77.6 ( 4.7% knockdown
(Figure 4d,e). Many gene transfection systems are
known to be cytotoxic due to their strong positive
charges. This study also found that Lipo2K or LipoMax
was associated with considerable cytotoxicity, showing
relatively low cell viability in the range of 54.8 ( 3.5 to
56.5 ( 3.8% at 5 pmol RNA dose (Figure 4c). However,
the CaP-HDz-NC system does not rely on positively
charged materials to incorporate RNAs; the system is
mainly composed of anionic biopolymer, hyaluronan.
For this reason, CaP-HDz/RNAs-NFs showed little cyto-
toxicity toward 143B, DU145, or HCT116 cells (81.9( 4.7
to 103.02 ( 3.4% viability at 5 pmol RNA dose) despite
their substantial RNAi eﬃcacy (Figure 4c and Supporting
Information Figure S7c). These results strongly support
our hypothesis that this newly engineered, versatile RNA
nanocarrier system could eﬀectively deliver a variety
of RNAs into cancer cells for RNAi applications. The NC
systemdemonstrates superior RNAdelivery eﬃciency to
the conventional gene transfecting agents as well as
signiﬁcantly lower cytotoxicity than Lipo2K or LipoMax.
The utility of this RNA delivery system is primarily
attributed to its tumor targetability and RNAi potency
in vivo. To demonstrate in vivo applications of the NF,
we investigated the biodistribution and tumor-target-
ing proﬁle of the CaP-HDz/RNA-NFs labeled with Cy5.5
in a HCT116 xenograft mouse model. HCT116 tumor-
bearing mice (n = 4) were intravenously injected with
Cy5.5-labeled NFs (280 μL; RNA = 700 pmol), where
siLuc was formulated with CaP-HDz-NCs as a model
RNA. It can be noted that, from 3 h post-administration
of Cy5.5-CaP-HDz/RNA-NFs, tumor was clearly deli-
neated by strong ﬂuorescence signals from the tumor
tissue, which increased until 6 h before decreasing.
Until 48 h post-injection, considerable ﬂuorescence
signal was still seen in the tumor sites (Figure 5a,b).
Ex vivo images also exhibited strong ﬂuorescence
intensities in the tumor tissue. Noticeable ﬂuorescence
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signal was also found in the liver and kidneys
(Supporting Information Figure S8a,b).
Furthermore, we studied the tumor-speciﬁc RNAi
eﬀect of CaP-HDz/RNA-NFs in a HCT116 xenograft mod-
el. We intravenously administered PBS, CaP-HDz/siLuc-
NFs, or CaP-HDz/siNC-NFs (280 μL; RNA = 700 pmol) into
the tumor-bearing mice. The fLuc gene silencing eﬃ-
ciencywas quantitatively estimatedby in vivoBLI. At 72 h
post-injection, the BL intensities from tumors of the
CaP-HDz/siLuc-NF group dramatically lessened, indicat-
ing signiﬁcant suppression of fLuc gene expression
but not from tumors of the other groups (PBS, CaP-
HDz/siNC-NF). The fLuc gene expression in the tumors of
CaP-HDz/siLuc-NF groupswas inhibited by79.4( 11.7%,
such that the bioluminescence signal was barely ob-
served in the tumors (Figure 5c,d). On theother hand, the
BL signals in the tumors of PBS and CaP-HDz/siNC-NF
groupswere greatly ampliﬁed. The fLuc gene expression
was augmented by 49.7 ( 3.3 and 32.3 ( 15.8% in the
PBS and CaP-HDz/siNC-NF groups, respectively, which
can account presumably dye to tumor cell proliferation.
The remarkable ability of CaP-HDz-NCs to deliver
RNAs is not conﬁned to siRNA delivery but can also be
applied to miRNA-based RNAi. To assess miR34a
transfection eﬃciency of CaP-HDz/miR34a-NFs, we
established a stable cell line transfected with a miR34a
imaging reporter system that generates a strong cel-
lular bioluminescence signal. Presence of intracellular
miR34a decreases the BL signals in a dose-dependent
manner. We quantitatively examined the intracellular
level of miR34a transfected by CaP-HDz-NCs or the
second-generation RNA transfection agent, LipoMax
(RNAiMAX), bymeasuringBL intensity inHCT116-miR34a
cells treated with CaP-HDz/miR34a-NFs or LipoMax/
miR34a. The CaP-HDz-NC system eﬀectively delivered
miR34a molecules into the cytoplasm. CaP-HDz/miR34a
could reach a 50% signal decrease with a miR34a dose
of 0.1 ( 0.003 pmol, whereas LipoMax requires almost
10 times higher miRNA dose of 1.2 ( 0.2 pmol to reach
the same eﬀect (Figure 6ad).
We also assessed the in vivo miRNA delivery activity
using CaP-HDz/miR34a-NF. CaP-HDz/miR34a-NFs were
systemically injected intomice bearingHCT116-miR34a
tumors. PBS or CaP-HDz/miRNC-NFs were also adminis-
tered as controls (280 μL; RNA = 700 pmol). After 24 h,
BL intensities at tumors of CaP-HDz/miR34a-NF group
Figure 4. Suppression of gene expression using CaP-HDz/siRNA-NF. Suppression of fLuc gene expression and viability of
143B-fLuc cells after treatment with siRNA (siLuc or siNC) only, CaP-HDz-NP or Lipo2K complexed with siLuc or siNC (a,b and
Supporting Information Figure S5a,b); *p < 0.005, **p < 0.05 vs control or Lipo2K/siLuc. CaP-HDz/siLuc group suppresses fLuc
genes more eﬃciently than the Lipo2K/siLuc or free siLuc group. The CaP-HDz-NP group also shows less toxicity compared
to the Lipo2K group at high concentrations (c and Supporting Information Figure S5c). Suppression eﬀect of CaP-HDz/
siRNA-NFswas conﬁrmedwith siGFP inDU145-GFP cells. Suppressionof GFPgeneexpressionofDU145-GFPcells byCaP-HDz-
NP or Lipo2K complexed with siGFP, siNC, or empty carriers (CaP-HDZ-NP or Lipo2K) without RNA complexation (df and
Supporting Information Figure S5d,e); *p < 0.005 vs control group or Lipo2K/siGFP group. The CaP-HDz/siGFP group shows
suppresion of the GFP gene expressionmore eﬃciently than the Lipo2K/siGFP group. However, the siNC or empty groups do
not show notable suppression eﬀect.
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substantially dropped by 52.9 ( 19.5%, indicating
eﬀective intracellular delivery of miR34a into tumor
cells by the NFs in vivo (Figure 6e,f). However, the BL
intensities from the control groups markedly increased
by 33.3 ( 10.2% (PBS) or 39.9 ( 7.9% (CaP-HDz/
siNC-NF). While measuring BL intensities, we did not
ﬁnd noticeable decrease in tumor size of all the groups,
implying that the decrease in BL signal was induced by
successful intracellular delivery of miRNA rather than
the cytotoxicity of the nanoformula.
Recently, we have also established advanced NFs
coloaded with chemo- and RNAi therapeutics for sy-
nergistic tumor therapy. As a proof-of-concept study,
the drug/RNA codelivery was monitored in HCT116
cancer cells (Supporting Information Figure S9). Both
a model drug, paclitaxel labeled with Oregon green
(OG-PTX), and Cy3-labeled siRNA could be delivered in
HCT116 cancer cells within 30 min after treatment,
showing rapid internalization of CaP-HDz/drug/
RNA-NFs. Furthermore, to validate therapeutic utility
of CaP-HDz/drug/RNA-NFs, we also formulated an
anticancer drug, doxorubicin (Dox), along with siMDR
in CaP-HDz nanoparticles (CaP-HDz/Dox/siMDR-NFs).
In an eﬀort to substantiate therapeutic potential
of the NFs, we investigated the RNAi eﬀects of the
CaP-HDz/RNA-NFs on a therapeutic target protein,
p-glycoprotein 1 (P-gp1) expression (also referred to
as multidrug resistance protein 1 (MDR1)), which is
known to be ascribed to multidrug resistance traits of
various cancer cells.30 We complexed MDR1-target
siRNA (siMDR) with CaP-HDz nanocarriers. After drug-
resistant OVCAR8 (OVCAR8/ADR) cells were treated
with CaP-HDz/siMDR-NFs, the MDR1 mRNA and P-gp1
expression levels were examined by qRT-PCT and
Western blot analyses. CaP-HDz/siMDR-NFs signiﬁ-
cantly down regulated both MDR1 mRNA and P-gp1
expression (Supporting Information Figure S10), which
indicates the recovery of sensitivity of OVCAR8/ADR
cells to drugs.
Furthermore, therapeutic activity of NFs coloaded
with Dox and siMDR (CaP-HDz/Dox/siMDR-NFs) was
evaluated in vitro by monitoring the viability of
Figure 5. In vivo monitoring of tumor-targeting and gene silencing eﬀect of CaP-HDz/siRNA-NFs. (a) In vivo near-infrared
ﬂuorescence (NIRF) imaging of HCT116 tumor-bearing mice systemically administered with CaP-HDz/siLuc-NFs labeled with
Cy5.5. (b) Quantitative analysis of ﬂuorescence intensities at the tumor site of mice treated with CaP-HDz/siLuc-NFs. The% ID
indicates the percentage of the injected dose. Error bars represent SD (n = 4). NIRF signals for the NFs at the tumor site were
strong enough to outline tumors. The NIRF imaging revealed that the NFs accumulated at the tumor site until 6 h and were
then slowly cleared from tumors. (c) In vivobioluminescence imaging (BLI) of fLuc gene expression in fLuc-expressingHCT116
tumor-bearing mice intravenously injected with PBS, free siLuc, or CaP-HDz/siLuc-NFs (280 μL; RNA = 700 pmol). (d)
Quantitative analysis of fLuc expression at tumors after intravenous injection of CaP-HDz/siLuc-NFs into the fLuc-expressing
HCT116 tumor mice (n = 4). The BL intensities from tumors of the CaP-HDz/siLuc-NF group signiﬁcantly decreased at 3 days
after injection, implying eﬀective suppression of fLuc gene expression but not from tumors of the other groups (PBS,
CaP-HDz/siNC-NF). Red arrow indicates tumor site; *p < 0.005, **p < 0.05 vs control or siNC.
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OVCAR8/ADR cells after treatment with free Dox, CaP-
HDz/Dox/siNC, or CaP-HDz/Dox/siMDR-NFs as well as
in vivo by measuring tumor volume of OVCAR8/
ADR xenografted mice after systemic administration
of saline, free Dox, CaP-HDz/Dox/siNC, or CaP-HDz/
Dox/siMDR-NFs. Treatment of CaP-HDz/Dox/siMDR-
NFs exhibited signiﬁcantly superior suppression eﬀects
not only on the OVCAR8/ADR tumor cell proliferation
(Figure 7a) in vitro but also on the growth of OVCAR8/
ADR tumor in vivo (Figure 7b) as compared to that of
free Dox, CaP-HDz/Dox, or CaP-HDz/Dox/siNC.
CONCLUSIONS
Development of nontoxic, tumor-targetable, and
potent in vivo RNAi delivery systems remains a formid-
able challenge. In this study, we developed a versatile
RNAi nanoplatform based on a tumor-targeting and pH-
responsive RNA nanoformula. The NF was engineered
by combination of tumor-targetedHAnanoparticlewith
an artiﬁcial RNA receptor, Zn(II)-DPA, which was further
protected with a CaP coating by in situ mineralization.
The NF can strongly secure RNAmolecules through the
Figure 6. Tumor-cell-speciﬁc miR34a delivery using CaP-HDz/miR34a-NFs. Delivery of miRNA into HCT116-fLuc-miR34a cells
by CaP-HDz-NP (a) or LipoMAX (b) complexed withmiR34a,miR-NC, or empty carriers without complexation. (c) Quantitative
analysis of miR34a delivery eﬃciency using a BLI technique. HCT116-fLuc-miR34a cells are designed to express strong BL
signals. Once miR34a is delivered into the HCT116 cells, it can bind with miR34a binding domain in the cells and rapidly
suppress BL signals, and thus the BL intensity can be used for quantiﬁcation of intracellular concentration of miR34a. (d)
Viability of HCT116 cells after treatmentof CaP-HDzor LipoMAXcomplexedwithmiRNA (5pmol) or empty carriers; *p<0.005,
**p<0.05 vs the control or LipoMAX/miRNAgroups. CaP-HDz/miR34a group suppresses fLuc signalsmore eﬃciently than the
LipoMAX/miR34a group. The CaP-HDz-NP group also shows less toxicity compared to the LipoMAX group at the high
concentration (5 pmol). (e) In vivo bioluminescence imaging of HCT116-fLuc-miR34a tumor-bearing mice intravenously
injectedwith PBS, freemiR34a, or CaP-HDz/miR34a-NFs (280 μL; RNA= 700 pmol). (f) Quantitative analysis ofmiR34a delivery
eﬃciency at tumors after intravenous injection of CaP-HDz/miR34a-NFs into the HCT116-fLuc-miR34a xenograft (n = 4). The
BL signals from tumors of the CaP-HDz/siLuc-NF group signiﬁcantly decreased in vivo as well as in vitro, suggesting eﬀective
miR34a delivery, but not from tumors of the other groups (PBS, CaP-HDz/siNC-NF); *p < 0.005 vs control or miRNC.
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artiﬁcial RNA receptors as well as the robust CaP coating
and also can target RNAs into the tumor cells in vivo
through both passive targeting and CD44-mediated
endocytosis. The NF can eventually distribute RNAs into
the cytosol of cancer cells, selectively suppressing target
gene expression. Unlike most reported gene delivery
systems, this NF system is not based on cationic deriva-
tives to incorporate nucleic acid derivatives, and thus
the NF demonstrated much lower nonspeciﬁc accumu-
lation and toxicity yet higher tumor targetability and
tumor-speciﬁc gene delivery eﬃcacy after systemic
administration than the conventional gene transfection
agents. This NF systemcanbeused asa versatile delivery
platform for RNAi and nanomedicine application, which
may open up new possibilities for RNA-based cancer
therapeutics.
METHODS
Chemical structures, synthesis schemes, and detailed experi-
mental methods are described in the Supporting Information.
All animal experiments were conducted in accordance with an
NIH approved protocol.
Materials. Sodium hyanluronate (Mw 200 K) was purchased
from Lifecore Biomedical (Chaska, MN, USA). Cells were pur-
chased from the American Type Culture Collection (Rockville,
MD, USA). The other chemicals and biological materials were
purchased from Sigma-Aldrich Co. (St. Louis, MO, USA) or
Invitrogen (Carlsbad, CA, USA) unless otherwise noted.
Synthesis of HDz Nanoparticle. HA-based nanoparticles conju-
gatedwith an artificial RNA receptor, DPA/Zn, were synthesized.
First, we synthesized amine-functionalized bis(DPA) molecules
and amphiphilic HA-CA conjugates. To prepare HA-based nano-
particles (HA-NPs), HA-CA conjugates (60 mg) were dispersed
in 12 mL of DW using a probe-type sonifier for 20 min. Second,
bis(DPA) molecules (15 mg, 27 μmol), as an RNA receptor, were
chemically conjugated onto HA-NPs through amide formation
in the presence of EDC (10.5 mg, 54 μmol) and sulfu-NHS
(17.6 mg, 81 μmol). The HA-NPs modified with DPA molecules
(HD-NPs) were purified by dialysis against distilledwater for 24 h
and were freeze-dried to get a dried white powder. Third, to
complex Zn ions with DPA ligands (HDz-NPs), zinc nitrate
hexahydrate (ZNH) (5 mL, 3 mg/mL, 10.1 mM) was mixed with
HD-NPs (5 mL, 2 mg/mL in UPW), and the resulting mixture was
incubated at 40 C under agitation for 30 min. The structure
and purity of the HDz conjugate were analyzed by 1H NMR and
RP-HPLC, respectively.
Formulation of Chemotherapeutics. HDz-NPs can be loaded with
biological therapeutics (RNAs) and chemotherapeutics (small-
molecule hydrophobic drugs). Small-molecule chemotherapeu-
tics can be encapsulated within the hydrophobic within HDz-
NPs by strong interaction between hydrophobic CA molecules
of NPs and hydrophobic drug molecules using a sonication
method in aqueous solution. To prepare drug/RNA coloaded
NFs, drug encapsulation should be preceded by RNA formula-
tion. First, we dispersed HDz conjugate in UPW at 5 mg/mL by
sonication using a probe-type sonifier for 20 min. Small-mole-
cule drug molecules (paclitaxel labeled with Oregon green
(PTX-OG) or doxorubicin (Dox)) dissolved in DMF (4 mg/mL)
were added dropwise into the HDz-NP solution (2 mL) during
sonication for 20 min. The solution was agitated for 30 min with
stirring and dialyzed against distilled water for 12 h using
dialysis tubing (1214 K MWCO) to remove DMF and unloaded
residues, followed by the freeze-dry. Drug contents in the NFs
were calculated by RP-HPLC after the nanoformulas were dis-
assembled in DW/DMF (1/1 v/v) cosolvent.
Formulation of RNA Therapeutics. To prepare HDz-NPs, we dis-
persed HDz conjugate (or HDz/PTX-NPs) in UPW at 1 mg/mL by
sonication using a probe-type sonifier for 20 min. The HDz-NP
solution (2 μL) was vigorously mixed with 1 μL of RNAs, that is,
firefly luciferase target siRNA (siLuc), microRNA-34a (miR34a),
or oligonucleotide 623 (Oligo-623), and the solution was incu-
bated at room temperature for 30 min. Moreover, we deposited
inorganic calcium phosphate (CaP) layers onto the nanoformu-
las by in situ mineralization method to provide further protec-
tion of RNA molecules. We added 1 μL of Tris-calcium buffer
(1 mM Tris, 250 m CaCl2, pH 7.6) and sequentially added 4 μL
of HEPES phosphate buffer (50 mM HEPES, 1.5 mM Na2HPO4,
pH 7.4) onto the HDz/siRNA nanoformulas. The solution was
vigorously agitated by pipetting. The CaP-doped HDz/RNA
(CaP-HDz/RNA or CaP-HDz/PTX/RNA) nanoformulas were trea-
ted for in vitro/in vivo application after incubated for 5 min at
room temperature.
Gene Silencing Effects of CaP-HDz/RNAs in Cells. We established
stabilized cell lines: 143B cells, DU145, and HCT116 cells expres-
sing firefly luciferase gene (fLuc), green fluorescence protein, or
miR34a reporter gene vector (143B-fLuc, DU145-GFP, HCT116-
fLuc, or HCT116-miR34a). 143B, DU145, and HCT116 cells were
Figure 7. Therapeutic activity of CaP-HDz/Dox/siMDR-NFs against Dox-resistant OVCAR8 cells. Antitumor eﬃcacy of CaP-
HDz/Dox/siMDR-NFs in drug-resistant OVCAR8/ADR cells (n = 6) (a) or in OVCAR8/ADR tumor-bearing mice (n = 4) (b) after
systemic administration of the NFs. OVCAR8/ADR tumor cells were remarkably sensitized to Dox when siMDR is formulated
with Dox in CaP-HD nanocarriers, showing signiﬁcantly improved therapeutic activity compared to the free Dox or CaP-HDz/
Dox/siNC; *p < 0.005 vs free Dox or CaP-HDz/Dox/siNC.
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maintained in MEM medium with 10% FBS at 37 C in a
humidified 5% CO2 atmosphere. Cells were transfected
with pcDNA3.1 expression vector modified with fLuc, GFP,
or with the inclusion of one miR34a perfect binding site
(ACAACCAGCTAAGACACTGCCA) in the 30 UTR of fLuc protein
using Lipo2K based on the protocol for Lipo2K provided by
the company (Invitrogen). We added the selection reagent
Geneticin (G418) onto the cells transfected with fLuc, GFP, or
miR34a vector, and colonies showing significant signals were
selected after monitoring fLuc or GFP expression level. To
confirm gene silencing effects of CaP-HDz/RNA nanoformulas,
we seeded cells in 96-well plates and treated the cells with
CaP-HDz/siLuc, CaP-HDz/GFP, or CaP-HDz/miR34a (8 μL; siRNA =
10 pmol) dispersed in 92 μL of the cell culture medium (MEM,
10% FBS). Cells were incubated for 24 h. Parallel experiments for
positive control (Lipo2K/siLuc, Lipo2K/GFP, or LipoMAX/miR34a)
and negative control (CaP-HDz/siNC or CaP-HDz/miNC) were
also carried out. After 24 h incubation, the fLuc or GFP signals in
the cellswere quantified using a flow cytometer (BDAccuri C6) or
a bioluminnescence imaging system (Xenogen IVIS-100), respec-
tively. Thebioluminescence or fluorescence intensity (BLI or FI) of
untreated cells is set as the 100%signal intensity, and the relative
BLI or FI is calculated to estimate the fLuc, GFP gene expres-
sion level, or intracellular miR34a level. The BLI signal intensity
is further normalized with live cell numbers. The cytotoxicity of
HDz/RNAs, CaP-HDz/RNAs, or Lipo/RNAswas assessed according
to the alamarBlue assay protocol.
In Vivo Gene Silencing Effects of CaP-HDz/RNAs. HCT116 tumor
xenograft models were prepared by subcutaneous injection of
5 106HCT116-miR34a cells in the right flank of female athymic
nude mice (1820 g). When the diameter of tumors reached
about 8 mm, CaP-HDz/siLuc or CaP-HDz/miR34a (280 μL; RNA =
700 pmol) was intravenously administrated into the mice. In
parallel, CaP-HDz/siNC, CaP-HDz/miNC (280μL; RNA=700pmol),
or 280 μL of PBS was also injected as control groups. The BLI was
visualized by Xenogen IVIS-100, and the relative fLuc expression
level was calculated as previously reported.24
In Vitro Cytotoxicity of CaP-HDz/Dox/siMDR-NFs. The cytotoxic ef-
fects of Dox, CaP-HDz/Dox/siNC, and CaP-HDz/Dox/siMDR
were evaluated using the alamarBlue assay (Life Technologies).
OVCAR8/ADR cells were seeded at a density of 1 104 cells/well
in 96-well flat-bottomed plates and incubated for 48 h. Cells
were washed twice with PBS and incubated in the culture
medium with various concentrations of Dox, CaP-HDz/Dox/
siNC, and CaP-HDz/Dox/siMDR for 48 h at 37 C. Cell viability
was evaluated according to the alamarBlue assay protocol.
In Vivo Antitumor Efficacy of CaP-HDz/Dox/siMDR-NFs. To evaluate
the antitumor efficacy of CaP-HDz/Dox/siMDR, OVCAR8/ADR
tumor-bearing mice were prepared: A suspension of 1  107
OVCAR8/ADR ovarian cancer cells was subcutaneously injected
into the right flank of 56 week old female athymic nude mice
(1820 g). When tumors reached ∼8 mm in diameter, each
treatment was injected five times every 3 days. Four treatment
groups: (i) saline (280 μL, the control group), (ii) free Dox (280 μL;
50 μg), (iii) CaP-HDz/Dox/siNC-NFs (280 μL; Dox = 50 μg; siNC
700 pmol), and (iv) CaP-HDz/Dox/siMDR-NFs (280 μL; Dox =
50 μg; siMDR 700 pmol). Tumor volumes were calculated as
a  b2/2, where a is the largest and b is the smallest diameter.
Statistical Analysis. The statistical significance of differences
among the groups tested was determined with Sigma Plot
using t-test. A p value less than 0.05 is considered significant and
is specified in the figures with an asterisk: *p < 0.005, **p < 0.05.
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